9-ING-41

• Description :

  9-ING-41 (Elraglusib) is a maleimide-based ATP-competitive and selective glycogen synthase kinase-3β (GSK-3β) inhibitor with an IC50 of 0.71 μM. 9-ING-41 significantly leads to cell cycle arrest, autophagy and apoptosis in cancer cells. 9-ING-41 has anticancer activity and has the potential for enhancing the antitumor effects of chemotherapeutic agents[1][2][3][4].

• Product Name Alternative :

  Elraglusib

• UNSPSC :

  12352005

• Hazard Statement :

  H301, H311, H331, H341

• Target :

  Apoptosis; Autophagy; GSK-3

• Type :

  Reference compound

• Related Pathways :

  Apoptosis; Autophagy; PI3K/Akt/mTOR; Stem Cell/Wnt

• Applications :

  Cancer-Kinase/protease

• Field of Research :

  Cancer

• Assay Protocol :

  https://www.medchemexpress.com/9-ing-41.html

• Purity :

  99.13

• Solubility :

  DMSO : 50 mg/mL (ultrasonic)

• Smiles :

  O=C(C(C1=COC2=CC=C(F)C=C12)=C3C4=CN(C)C5=C4C=C6C(OCO6)=C5)NC3=O

• Molecular Formula :

  C22H13FN2O5

• Molecular Weight :

  404.35

• Precautions :

  H301, H311, H331, H341

• References & Citations :

  [1]Ugolkov AV, et al. 9-ING-41, a small-molecule glycogen synthase kinase-3 inhibitor, is active in neuroblastoma. Anticancer Drugs. 2018 Sep;29 (8) :717-724.|[2]Wu X, et al. Targeting glycogen synthase kinase 3 for therapeutic benefit in lymphoma. Blood. 2019 Jul 25;134 (4) :363-373.|[3]Irina N Gaisina, et al. From a natural product lead to the identification of potent and selective benzofuran-3-yl- (indol-3-yl) maleimides as glycogen synthase kinase 3beta inhibitors that suppress proliferation and survival of pancreatic cancer cells. J Med Chem. 2009 Apr 9;52 (7) :1853-63.|[4]Hiroo Kuroki, et al. 9-ING-41, a small molecule inhibitor of GSK-3beta, potentiates the effects of anticancer therapeutics in bladder cancer. Sci Rep. 2019 Dec 27;9 (1) :19977.

• Shipping Conditions :

  Room Temperature

• Storage Conditions :

  -20°C, 3 years; 4°C, 2 years (Powder)

• Scientific Category :

  Reference compound1

• Clinical Information :

  Phase 2

• Isoform :

  GSK-3β

• CAS Number :

  [1034895-42-5]